Online inquiry

IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4447MR)

This product GTTS-WQ4447MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CTLA4 gene. The antibody can be applied in Renal cell carcinoma (RCC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001037631.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1493
UniProt ID P16410
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ4447MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ7190MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
GTTS-WQ5011MR IVTScrip™ mRNA-Anti-GP, c4G7-N(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA c4G7-N
GTTS-WQ633MR IVTScrip™ mRNA-Anti-IL9, 7F3com-2H2(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 7F3com-2H2
GTTS-WQ5632MR IVTScrip™ mRNA-Anti-TNF, CDP870(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CDP870
GTTS-WQ494MR IVTScrip™ mRNA-Anti-IGHE, 47H4(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA 47H4
GTTS-WQ7958MR IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GX-17
GTTS-WQ12855MR IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OPN-305
GTTS-WQ7366MR IVTScrip™ mRNA-Anti-FZD7, FZD8-Fc(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FZD8-Fc
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW